A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study.

Trial Profile

A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-1
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 18 Jan 2014 Primary endpoint 'Overall-survival-duration' has not been met.
    • 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top